Company: CDT
Filing Date: 2025-04-16
Form Type: 8-K
Source: 0001641172-25-005036
Chunk: 2

Company: CDT Equity Inc.
Filing Date: 2025-04-16
Form: 8-K
Item: Item 5.02
Chunk 2
---
 does not have an equity or ownership interest in Sarborg. Except for the Sarborg Agreement and the Additional Agreement, Dr.
Regan has no direct or indirect material interest in any other transaction required to be disclosed pursuant to Item 404(a) of Regulation
S-K.

The
foregoing description of the Sarborg Agreement and Additional Agreement is not complete and is qualified in its entirety by reference
to the full text of the Sarborg Agreement, a copy of which is filed as Exhibit 10.34 to the Company’s Annual Report on Form 10-K,
filed with the Securities and Exchange Commission on March 28, 2025, and is incorporated by reference herein, and the Additional Agreement,
a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

There
are no arrangements or understandings between Dr. Regan and any other persons pursuant to which he was appointed as Chief Executive Officer
of the Company. There are no family relationships between Dr. Regan and any other director or executive officer of the Company.

Resignation
of Faith Charles

On
April 16, 2025, Ms. Charles notified the Board of her resignation due to personal reasons, and as a result will resign as a member of
the Board of the Company and from all committees on which she served, effective immediately. Ms. Faith’s resignation was not due
to any disagreement with management or the Company’s operations, policies or practices.

Following
the resignations of Dr. Tapolczay and Ms. Charles, the Board was reduced from seven to five members.

Item
7.01 Regulation FD.